S & N ceases U.S. distribution of Ranasys


Smith & Nephew (SNN -1.7%) temporarily ceases distribution of the Renasys Negative Pressure Wound Therapy product line in the U.S. The stoppage is per instructions from the FDA that Renasys needs new 510(k) regulatory clearance because of design enhancements that have been made to the product. The company has filed the relevant paperwork and awaits the agency's action.

Renasys' U.S. sales represented <5% of global Advanced Wound Management revenue in 2013.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs